From the Art of Medicine to the Science of Psychiatry: Measurement-Based Care Strategies for Depression

src="https://www.123enroll.com/custImages/237175/7058ProgramLogo.jpg"

For venue information, please click on the venue name below.


The Art Insitute of Chicago • Chicago • Saturday, October 18

City Club of San Francisco • San Francisco • Saturday, November 15

The Colburn School of Performing Arts • Los Angeles • Saturday, February 7

New York Academy of Sciences • Manhattan • Saturday, April 4

John F. Kennedy Presidential Library • Boston • Saturday, April 18


This activity is supported by an unrestricted educational grant from
Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Faculty

Co-chairs:

Charles B. Nemeroff, MD, PhD
Reunette W. Harris Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GA

Madhukar H. Trivedi, MD
Associate Professor in Psychiatry
Director, Mood Disorders Research Program and Clinic
Department of Psychiatry
University of Texas Southwestern Medical Center – Dallas
Dallas, TX

Distinguished Faculty:

Ned H. Kalin, MD
Hedberg Professor and Chair, Department of Psychiatry
Director, HealthEmotions Research Institute
Department of Psychiatry
University of Wisconsin-Madison
Madison, WI

William M. McDonald, MD
Chief, Division of Geriatric Psychiatry
Emory Healthcare
Director, Fuqua Center for Late Life Depression
Emory University School of Medicine
Atlanta, GA

John W. Newcomer, MD
Professor of Psychiatry, Psychology, and Medicine
Medical Director of the Center for Clinical Studies
Washington University School of Medicine
St. Louis, MO

Maria A. Oquendo, MD
Professor of Clinical Psychiatry
Vice Chair for Education
Columbia University College of Physicians & Surgeons
Director, Clinical Studies in Molecular Imaging and Neuropathology Division
New York State Psychiatric Institute
New York, NY

Mark H. Rapaport, MD
Chairman, Department of Psychiatry and Behavioral Neurosciences
Cedars-Sinai Medical Center
Los Angeles, CA

Zachary N. Stowe, MD
Professor of Psychiatry and Behavioral Sciences
Professor of gynecology and Obstetrics
Director, Women’s Mental Health Program
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GA

Michael E. Thase, MD
Professor of Psychiatry
University of Pittsburgh Medical Center and Western Psychiatric Institute and Clinic
Pittsburgh, PA

Statement of Need and Program Overview

The public health implications of depression are profound. Depression currently ranks as the 4th leading global disease burden, according to the Global Burden of Disease Study, and by 2020 is projected to rise to the second disease burden worldwide. Already, major depressive disorder (MDD) is the leading cause of disability in the US among adults, affecting nearly 15 million people. Those who seek therapy are prescribed antidepressants, the mainstay of depression treatment. Yet two-thirds of all individuals when first prescribed antidepressants fail to remit, finding these initial treatments to be incomplete or inadequate as typified in the large, NIMH-funded, real-world trial “Sequenced Treatment Alternatives to Relieve Depression (STAR*D)”. Remitters to subsequent levels of therapy, according to the proscribed stepped-care approach, became progressively fewer (2nd step: <30%; 3rd and 4th steps ~15%). Treatment of depression should entail a sequenced treatment (with an adequate duration) approach leading to either a switch to another antidepressant or augmentation of the first treatment with another agent. Despite this, there exists a need for new therapies/strategies in treatment-resistant depression (TRD).

Since no one treatment is effective for all patients, optimal implementation focusing on the measurement of symptoms, side effects, and function is essential to determine effective sequential treatment approaches. There is a need for a paradigm shift in how clinical decision making is incorporated into practice and for a departure from the “trial-and-error” approach that currently determines the "next-best" treatment. Several decision-making strategies include those described by the STAR*D trial and the Texas Medication Algorithm Project (TMAP). To further enhance adherence to these guidelines, an electronic decision support system that provides critical feedback and guidance at the point of patient care has been developed. Such a measurement-based care (MBC) approach is essential to any decision support system. Successful integration of sequential algorithms with MBC into real-world clinics will allow clinicians to individualize and constantly adapt decisions about patient care based upon symptom progress, tolerability of medication, and dose optimization, and ultimately improve patient outcome.

This CME series From the Art of Medicine to the Science of Psychiatry: Measurement-Based Care Strategies for Depression to be co-chaired by Drs Madhukar Trivedi (Chief, Division of Mood Disorders, University of Texas Southwestern Medical School) and Charles Nemeroff (Chair, Department of Psychiatry, Emory University) will highlight the pivotal trials and novel approaches to treatment refractory depression (TRD) and will feature challenging cases in patient populations with co-existing conditions as well as cases that support and illustrate the use of an iterative MBC approach to TRD.

Target Audience

Psychiatrists, physicians, nurses and other healthcare professionals involved in the care of patients with mental illness.

Learning Objectives

After participating in this activity, the clinician will be able to:

Review STAR*D data on augmentation approaches in treatment resistant depression (TRD);
Provide evidence-based support for second-generation antipsychotic augmentation and appropriate use in combination with antidepressants;

Highlight comorbid factors and considerations that impact antidepressant treatment selection in patients with physical and psychiatric comorbidities;

Summarize the use of algorithms and measurement-based care approaches to TRD;

Describe future and emerging therapeutic approaches to optimize remission from depression.

Agenda

8:30 am - 9:00 am	Registration and Continental Breakfast
9:00 am – 9:10 am	Welcome and Introduction by Program Chair
9:10 am – 9:55 am	*Augmentation Approaches Evaluated in STARD**
9:55 am – 10:10 am	Refreshment Break
10:10 am – 10:55 am	Efficacy and Safety of Antipsychotic Augmentation
10:55 am – 12:00 pm	Depression in Comorbid Populations: Challenging Patient Case Studies
12:00 pm – 1:00 pm	Luncheon
1:00 pm – 1:45 pm	Measurement-Based Care Approaches to Improving Outcomes: Challenging Patient Case Studies
1:45 pm – 2:30 pm	Towards Recovery Goal: Future Horizons in Depression
2:30 pm – 3:15 pm	Panel Discussion: Questions & Answers

Accreditation

Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of North Texas Health Science Center (UNTHSC) and Letters & Sciences. The UNTHSC is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The UNTHSC designates this continuing medical education activity for a maximum of 5.0 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Continuing Nursing Education
Letters & Sciences is an approved provider of continuing nursing education by the New Jersey State Nurses Association (NJSNA), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider Number P205-5/07-10. This activity is designated for 5.0 contact hours. Letters & Sciences is an approved provider by the California Board of Registered Nursing. Provider Number CEP14145. This activity is designated for 5.0 contact hours.

Americans With Disabilities Act

The Letters & Sciences Event Staff will assist those whose attendance may require special services. Call 800-238-9620 PIN #7058 prior to the event for special accommodations.

We DO NOT sell or distribute any personal information on our system and it will only be shared with program manager(s) for this specific event, at which time all information is then protected by their individual privacy policies. During registration all users are required to give their contact information. This information is used ONLY to contact the users with information related to this specific event. When users submit sensitive information via this site, that information is encrypted and is protected with the best encryption software in the industry–SSL.